Background: Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms.
Methods: Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4-8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 +/- 17 d).
Results: All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P < 0.01).
Conclusion: The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eurpsy.2004.06.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Cochrane Database Syst Rev
October 2022
Complex Care and Recovery, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada.
Article Synopsis
- Antipsychotic-induced weight gain is prevalent among individuals with schizophrenia, leading to serious health complications, prompting the need for effective management strategies.
- This review aims to evaluate the effectiveness of pharmacological interventions specifically designed to prevent weight gain associated with antipsychotic medications in schizophrenia patients.
- The review includes 17 randomized controlled trials and assesses various outcomes related to weight changes and compliance, although many of the primary outcomes were infrequently reported in the studies.
Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials.
Pharmacopsychiatry
January 2020
Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China.
Background: Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent.
Aim: The aim of this study was to examine the efficacy and tolerability of reboxetine as an adjunct medication to antipsychotic treatment in a meta-analysis of randomized controlled trials (RCTs).
Methods: Two independent investigators extracted data for a random effects meta-analysis and assessed the quality of studies using risk of bias and the Jadad scale.
Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor.
Ther Adv Psychopharmacol
October 2015
Razi Psychiatric Hospital, Tehran, Iran.
Objective: Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with schizophrenia and their management is not unproblematic. Reboxetine is a norepinephrine reuptake inhibitor (NRI). Previous studies regarding the useful effects of reboxetine on deficit symptoms of schizophrenia have resulted in inconsistent results.
View Article and Find Full Text PDFEffects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice.
Pharmacol Biochem Behav
December 2015
Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD 57007, USA. Electronic address:
Evidence suggests that lobeline, a nicotinic acetylcholine receptor ligand, has antidepressant-like properties in mice. The present study investigated the possible additive or synergistic effects of lobeline in combination with commonly used antidepressants, such as reboxetine, fluoxetine, or bupropion, using the tail suspension test (TST) and the forced swim test (FST) in C57BL/6J mice. Reboxetine (5 or 10 mg/kg, i.
View Article and Find Full Text PDFEfficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.
ScientificWorldJournal
April 2016
Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-Dong, Dongjak-Gu, Seoul 156-756, Republic of Korea.
Objectives: This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics.
Methods: Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!